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ABSTRACT: We report the synthesis and character-
ization of a bimetallic conjugate (RhPt) in which an
oxaliplatin derivative is tethered to a rhodium metal-
loinsertor through an aminomalonate leaving group ligand.
The complex interacts with DNA through metalloinsertion
at a base pair mismatch followed by formation of a
covalent Pt−DNA adduct. Characterization of RhPt in
mismatch repair-deficient HCT116O cells reveals in-
creased cytotoxicity compared to cisplatin and oxaliplatin
as well as relative to the unconjugated rhodium and
platinum counterparts. Caspase and poly-ADP ribose
polymerase inhibition assays indicate that RhPt induces
apoptotic cell death. Inductively coupled plasma mass
spectrometry (ICP-MS) experiments reveal that RhPt
exhibits enhanced cellular uptake properties that contrib-
ute to its increased efficacy.
Platinum anticancer compounds are among the mostsuccessful and most widely used chemotherapeutics to
date.1 However, cancers that exhibit deficiencies in the DNA
mismatch repair (MMR) pathway, including 15% of sporadic
colorectal cancer cases and 18% of all solid tumors, have
encountered limited success in treatment with classical platinum
therapeutics.2,3 Such cancers are largely resistant to cisplatin and
only marginally responsive to oxaliplatin.4,5
Rhodium metalloinsertors may offer a promising strategy in
the development of new therapies for such cancers. These bulky,
octahedral complexes bind specifically to DNA base pair
mismatches,6 which are amplified in cells with defective MMR
machinery.2,3 Metalloinsertors exhibit cytotoxicity preferentially
in MMR-deficient cells, and the extent of this selectivity
correlates with mismatch binding affinity and localization to
the nucleus, where they target mismatches in genomic DNA.7,8
The design of bifunctional drug conjugates is a burgeoning
field in chemotherapy, especially as a strategy to circumvent
resistance.9 Here, we present a bimetallic oxaliplatin−metal-
loinsertor conjugate (RhPt) that displays dual DNA binding
behavior. Additionally, RhPt exhibits enhanced cytotoxicity and
cellular uptake in MMR-deficient HCT116O cancer cells
compared to first-line platinum therapeutics as well as its
unconjugated subunits. The cytotoxicity of RhPt appears to be
triggered by an apoptotic cell death pathway, and its potency is
attributed to the improved cellular uptake of the complex.
The RhPt conjugate, shown in Figure 1, consists of a
trisheteroleptic Rh(III) scaffold tethered to an oxaliplatin
derivative by an aminomalonate leaving group ligand. RhPt
was constructed via a linear synthesis in which the rhodium
scaffold was first functionalized with the aminomalonate,
followed by complexation to platinum (see the Supporting
Information).10 The platinum unit employs the same (1R,2R)-
1,2-diaminocyclohexane nonleaving group ligand as oxaliplatin
and, therefore, is expected to form the same DNA adducts.11 The
rhodium unit contains a sterically expansive 5,6-chrysene diimine
ligand (chrysi), which is responsible for the recognition of DNA
mismatches.12 Too wide to intercalate into well-matched DNA,
the chrysi complexes instead target thermodynamically destabi-
lized mismatches from the minor groove, ejecting the bases from
the duplex in a binding mode known as metalloinsertion.13 The
aminomalonate linker is tethered to one of the noninserting
ancillary ligands, which allows the conjugate to remain intact
temporarily but ultimately enables the release of platinum, via
hydrolysis, for DNA binding. The biological activity of RhPt was
compared to several complexes, including cisplatin and
oxaliplatin (Figure 1). The rhodium hydrolysis product,
Rh(Amal), was included as a control to test whether the
biological activity of RhPt may be attributed to the intact
conjugate and not premature hydrolysis of the subunits. The
unconjugated platinum complex, Pt(Amal) was included to
explore the effects of the aminomalonate ligand on activity.
DNA binding studies were performed with RhPt and
radiolabeled duplex DNA containing a CC mismatch (Figure
2). As RhPt does not cleave DNA upon irradiation, a competition
titration was carried out using rac-[Rh(bpy)2chrysi]
3+, which
does photocleave DNA at the site of a mismatch.6 RhPt inhibits
photocleavage by rac-[Rh(bpy)2chrysi]
3+ at the mismatched site;
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Figure 1. Chemical structures of complexes studied.
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this indicates that RhPt binds specifically to the mismatch via
metalloinsertion. The binding affinity of RhPt for a CCmismatch
was determined to be 1.1 × 107 M−1 (Figure S1, Supporting
Information), comparable to that of monomeric metalloinser-
tors.8 DNA binding by the conjugate also involves the formation
of covalent adducts. Platination of the DNA is indicated by the
appearance of bands with reduced electrophoretic mobility,
located above the unmodified parent bands (Figures 2 and S2,
Supporting Information).14 Platinum binding to DNA was
further characterized by dimethyl sulfate (DMS) footprinting.
DMSmethylates theN7 position of guanine, resulting in cleavage
at those sites upon treatment with piperidine.15 At a 1:1 molar
ratio of DNA and RhPt (Figure 2), the guanine residues on the
labeled strand are protected from cleavage, signifying the
formation of platinum 1,2-intrastrand adducts at the N7
positions of the d(GpG) site, as is the case for oxaliplatin.16,17
That RhPt performs noncovalent metalloinsertion and covalent
platinum binding establishes the bifunctionality of the conjugate.
The lack of interplay between the rhodium and platinum binding
modes suggests that each subunit functions independently and
without inhibition of the other; that is, platinum binding does not
alter the apparent equilibrium of metalloinsertion in the minor
groove, nor does rhodium binding impede DNA platination.
The antiproliferative effects of RhPt were explored in the
isogenic human colorectal carcinoma cell lines HCT116N
(MMR-proficient) and HCT116O (MMR-deficient) using an
antibody assay for DNA synthesis.18 RhPt exhibits antiprolifer-
ative activity similar to that of oxaliplatin and considerably
outperforms cisplatin, which preferentially targets HCT116N
cells (Figure S3, Supporting Information). RhPt does not
preferentially target either cell line. However, it is active at
submicromolar concentrations and, in fact, is more potent than
either of its unconjugated subunits (Figure S4, Supporting
Information). Furthermore, RhPt exhibits enhanced cytotoxicity
(LC50 = 9 μM) over cisplatin (30 μM) and oxaliplatin (28 μM) in
MMR-deficient cells and is also substantially more potent than
Rh(Amal) (43 μM) and Pt(Amal) (57 μM) (Table S1 and
Figure S5, Supporting Information).
Cellular uptake was examined via inductively coupled plasma
mass spectrometry (ICP-MS) (Figure 3). The cellular uptake of
both rhodium and platinum for RhPt generally exceeds that of
the monomeric complexes, with RhPt displaying high initial
uptake that decreases over time, possibly due to an efflux
mechanism.19 Furthermore, the differences in uptake between
RhPt and hydrolysis product Rh(Amal) suggest that the
conjugate does not hydrolyze prior to entry into the cell and is
taken up in its intact form. Overall, it would appear that RhPt
possesses enhanced cellular uptake properties not inherent to
either subunit alone. The localization of each complex was also
examined (Table S1, Supporting Information). Little differ-
entiation is observed in the subcellular distribution of the
complexes, with the notable exception of a substantial increase in
the nuclear rhodium concentration of RhPt compared to
Rh(Amal). Curiously, this enhanced nuclear targeting of
rhodium does not result in cell-selective activity.
To further understand the biological activity of RhPt, we
examined the mechanism of cell death. It has been previously
established that rhodium metalloinsertors trigger necrosis
dependent upon DNA repair protein poly-ADP ribose polymer-
ase (PARP).7 Cytotoxicity studies revealed that the viability of
cells treated with RhPt does not increase in the presence of PARP
inhibitor DPQ,20 suggesting PARP-independent cell death
(Figure 4).21 The assay was also performed with the caspase
Figure 2. DNA binding of RhPt. Left: Competition titration of
increasing concentrations of RhPt (0−50 μM) with 1 μM rac-
[Rh(bpy)2chrysi]
3+ on 1 μM 5′-[32P] labeled 17mer duplex DNA
with a CC mismatch. Controls without irradiation (Øhν), and without
Rh (ØRh) were included. RhPt inhibits photocleavage by [Rh-
(bpy)2chrysi]
3+ at the mismatched site. Right: DMS footprinting of
duplex DNA containing a CC mismatch. Lanes (left to right): Maxam−
Gilbert sequencing (C+T; A+G); 3, DMS alone; 4, oxaliplatin (1 μM);
5, RhPt (1 μM); 6, RhPt (50 μM). Bands of high electrophoretic
mobility indicate cleavage at guanine residues; covalent binding of
platinum to guanine inhibits cleavage.
Figure 3. Cellular accumulation of metal complexes in HCT116O cells.
Rh and Pt counts were normalized to cellular protein: (left) whole-cell
uptake of Pt complexes as a function of time; (right) whole-cell uptake of
Rh for RhPt and hydrolysis product Rh(Amal).
Figure 4. Cell viability in HCT116O cells after 72 h with PARP and
caspase inhibitors. Viability is normalized to untreated controls. Left
(gray): PARP inhibition assay. Cells were treated with 0 or 20 μMRhPt
and 0, 25, or 50 μM DPQ. DPQ does not increase the viability of cells
treated with RhPt. Right (blue): Caspase inhibition assay. Cells were
treated with 0, 10, or 20 μM RhPt and 0 or 20 μM Z-VAD-FMK. Z-
VAD-FMK increases viability in RhPt-treated cells. Addition of either
inhibitor alone does not affect viability. *p < 0.0001(unpaired two-tailed
t test).
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inhibitor Z-VAD-FMK.22 The viability of RhPt-treated cells
increases in the presence of Z-VAD-FMK, signifying that RhPt
triggers caspase-dependent death (Figure 4). This is consistent
with studies of platinum cytotoxicity generally; it is well
established that cisplatin and oxaliplatin typically trigger
apoptosis.23 This result may, in part, explain the lack of cell-
selectivity observed for RhPt. By initiating apoptosis, rather than
necrosis, it is possible that the highly selective biological response
to mismatch recognition by rhodium is overridden by the effects
of high concentrations of platinum in the cell.
In this work, we examined the biological effects of conjugation
of a DNA metalloinsertor with a platinum drug. In vitro, the
complex successfully exhibits bifunctionality via dual DNA
binding. In MMR-deficient cells, this strategy affords enhanced
cellular uptake and potency over the individual subunits as well as
versus traditional chemotherapeutics. However, RhPt is not
without its limitations. The platinum subunit appears to
dominate the cellular response, resulting in a loss of cell
selectivity. Nevertheless, the biological analysis of RhPt provides
insight into the behavior of bifunctional DNA targeting agents as
well as a foundation for the design of future conjugates that are
both potent and selective in their cellular targeting.
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